Mabion Wins International CDMO Leadership Award in Biologics at DCAT Week

• Mabion has been named the Champion in the Biologics – International category at the 2025 CDMO Leadership Awards.

• The award was presented during DCAT Week in New York City and is based on client feedback evaluating quality, expertise, service, and reliability.

Mabion has been named the Champion of the 2025 International CDMO Leadership Award in Biologics. The award, which recognises excellence in contract manufacturing, highlights the company’s commitment to delivering high-quality biologics development and manufacturing services to pharmaceutical and biotech clients.

Organised by Life Science Connect, Outsourced Pharma, and Orientation Marketing, the CDMO Leadership Awards evaluate more than 210 CDMOs based on direct client feedback. Companies are assessed across key criteria, including quality, expertise, service, and reliability. Mabion stood out in the Biologics – International category, reinforcing its reputation as a trusted partner in the sector.

Adam Pietruszkiewicz, Chief Commercial Officer of Mabion, personally accepted the award during DCAT Week in New York City, a global pharmaceutical industry event. The gathering provided an opportunity to celebrate the achievement and engage with industry leaders.

“This award is a reflection of the trust and confidence our partners place in us,” Mabion stated in its announcement. “Their support fuels our passion for innovation and motivates us to push the boundaries of biologics development and manufacturing.”